Topical hypopigmenting agents for pigmentary disorders and their mechanisms of action

Annals of Dermatology

Volumn 24, Issue 1, 2012, Pages 1-6

  Kim, Hyojin ^a   Choi, Hye Ryung ^a   Kim, Dong Seok ^b   Park, Kyoung Chan ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Chung Ang University   (South Korea)

Author keywords

Hydroquinone; Hypopigmentation; Melanin

Indexed keywords

EID: 84863162166     PISSN: 10139087     EISSN: None     Source Type: Journal    
DOI: 10.5021/ad.2012.24.1.1     Document Type: Review

References (50)

1. Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol 2006;55:1048-1065. (Pubitemid 44716465)
2. Amer M, Metwalli M. Topical hydroquinone in the treatment of some hyperpigmentary disorders. Int J Dermatol 1998;37:449-450. (Pubitemid 28284878)
3. Rendon MI. Utilizing combination therapy to optimize melasma outcomes. J Drugs Dermatol 2004;3(5 Suppl):S27-34.
4. Bolognia JL, Sodi SA, Osber MP, Pawelek JM. Enhancement of the depigmenting effect of hydroquinone by cystamine and buthionine sulfoximine. Br J Dermatol 1995;133:349-357.
5. Briganti S, Camera E, Picardo M. Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Res 2003;16:101-110. (Pubitemid 36596955)
6. Kang HY, Valerio L, Bahadoran P, Ortonne JP. The role of topical retinoids in the treatment of pigmentary disorders: an evidence-based review. Am J Clin Dermatol 2009;10:251-260.
7. Kim DS, Kim HJ, Choi KH, Chung JH, Kim KH, Par KC. UVB-induced GM-CSF production is suppressed by dexamethasone in HaCaT cells. Photodermatol Photoimmunol Photomed 2001;17:121-125. (Pubitemid 32492740)
8. Lee IW, Lee SC, Kim DS, Kim HJ, Park KC. Effects of dexamethasone on endothelin-1 (ET-1) production by keratinocytes. Ann Dermatol 2001;13:148-152.
9. Torok HM. A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream. Am J Clin Dermatol 2006;7:223-230. (Pubitemid 44231917)
10. Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 2003;72:67-72. (Pubitemid 37229761)
11. Grimes P, Kelly AP, Torok H, Willis I. Community-based trial of a triple-combination agent for the treatment of facial melasma. Cutis 2006;77:177-184. (Pubitemid 43561381)
12. Torok HM, Jones T, Rich P, Smith S, Tschen E. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis 2005;75:57-62. (Pubitemid 40223103)
13. Hexsel D, Arellano I, Rendon M. Ethnic considerations in the treatment of Hispanic and Latin-American patients with hyperpigmentation. Br J Dermatol 2006;156 Suppl 1:7-12. (Pubitemid 44809123)
14. Chan R, Park KC, Lee MH, Lee ES, Chang SE, Leow YH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol 2008;159:697-703.
15. Yasumoto K, Yokoyama K, Takahashi K, Tomita Y, Shibahara S. Functional analysis of microphthalmia-associated transcription factor in pigment cell-specific transcription of the human tyrosinase family genes. J Biol Chem 1997;272:503-509. (Pubitemid 27021187)
16. Kim DS, Hwang ES, Lee JE, Kim SY, Kwon SB, Park KC. Sphingosine-1- phosphate decreases melanin synthesis via sustained ERK activation and subsequent MITF degradation. J Cell Sci 2003;116:1699-1706.
17. Kim DS, Park SH, Park KC. Transforming growth factor-beta1 decreases melanin synthesis via delayed extracellular signalregulated kinase activation. Int J Biochem Cell Biol 2004;36:1482-1491.
18. Kim DS, Park SH, Kwon SB, Youn SW, Park KC. Effects of lysophosphatidic acid on melanogenesis. Chem Phys Lipids 2004;127:199-206.
19. Kim DS, Kim SY, Moon SJ, Chung JH, Kim KH, Cho KH, et al. Ceramide inhibits cell proliferation through Akt/PKB inactivation and decreases melanin synthesis in Mel-Ab cells. Pigment Cell Res 2001;14:110-115.
20. Kim DS, Kim SY, Chung JH, Kim KH, Eun HC, Park KC. Delayed ERK activation by ceramide reduces melanin synthesis in human melanocytes. Cell Signal 2002;14:779-785.
21. Mishima Y, Imokawa G. Selective aberration and pigment loss in melanosomes of malignant melanoma cells in vitro by glycosylation inhibitors: premelanosomes as glycoprotein. J Invest Dermatol 1983;81:106-114. (Pubitemid 13026312)
22. Franchi J, Coutadeur MC, Marteau C, Mersel M, Kupferberg A. Depigmenting effects of calcium D-pantetheine-S-sulfonate on human melanocytes. Pigment Cell Res 2000;13:165-171. (Pubitemid 30400282)
23. Sugai T. Clinical effects of arbutin in patients with chloasma (in Japanese). Hifu (Skin Res) 1992;34:522-529.
24. Chakraborty AK, Funasaka Y, Komoto M, Ichihashi M. Effect of arbutin on melanogenic proteins in human melanocytes. Pigment Cell Res 1998;11:206-212. (Pubitemid 128531454)
25. Moon KY, Ahn KS, Lee J, Kim YS. Kojic acid, a potential inhibitor of NF-kappaB activation in transfectant human HaCaT and SCC-13 cells. Arch Pharm Res 2001;24:307-311. (Pubitemid 33703578)
26. Kim DS, Kim SY, Park SH, Choi YG, Kwon SB, Kim MK, et al. Inhibitory effects of 4-n-butylresorcinol on tyrosinase activity and melanin synthesis. Biol Pharm Bull 2005;28:2216-2219.
27. Huh SY, Shin JW, Na JI, Huh CH, Youn SW, Park KC. Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial. J Dermatol 2010;37:311-315.
28. Fenoll LG, Rodríguez-López JN, Varón R, García-Ruiz PA, García-Cánovas F, Tudela J. Action mechanism of tyrosinase on meta-and para-hydroxylated monophenols. Biol Chem 2000;381:313-320. (Pubitemid 30254493)
29. Ando H, Ryu A, Hashimoto A, Oka M, Ichihashi M. Linoleic acid and alpha-linolenic acid lightens ultraviolet-induced hyperpigmentation of the skin. Arch Dermatol Res 1998;290:375-381. (Pubitemid 28408561)
30. Ando H, Funasaka Y, Oka M, Ohashi A, Furumura M, Matsunaga J, et al. Possible involvement of proteolytic degradation of tyrosinase in the regulatory effect of fatty acids on melanogenesis. J Lipid Res 1999;40:1312-1316. (Pubitemid 29328534)
31. Ando H, Wen ZM, Kim HY, Valencia JC, Costin GE, Watabe H, et al. Intracellular composition of fatty acid affects the processing and function of tyrosinase through the ubiquitinproteasome pathway. Biochem J 2006;394:43-50. (Pubitemid 43259654)
32. Ando H, Watabe H, Valencia JC, Yasumoto K, Furumura M, Funasaka Y, et al. Fatty acids regulate pigmentation via proteasomal degradation of tyrosinase: a new aspect of ubiquitinproteasome function. J Biol Chem 2004;279:15427-15433. (Pubitemid 38618942)
33. Martínez-Esparza M, Ferrer C, Castells MT, García- Borrón JC, Zuasti A. Transforming growth factor beta1 mediates hypopigmentation of B16 mouse melanoma cells by inhibition of melanin formation and melanosome maturation. Int J Biochem Cell Biol 2001;33:971-983. (Pubitemid 32706689)
34. Seiberg M, Paine C, Sharlow E, Andrade-Gordon P, Costanzo M, Eisinger M, et al. Inhibition of melanosome transfer results in skin lightening. J Invest Dermatol 2000;115:162-167. (Pubitemid 30637183)
35. Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Dermatol 2002;147:20-31. (Pubitemid 34779433)
36. Imokawa G, Kobayashi T, Miyagishi M, Higashi K, Yada Y. The role of endothelin-1 in epidermal hyperpigmentation and signaling mechanisms of mitogenesis and melanogenesis. Pigment Cell Res 1997;10:218-228. (Pubitemid 127524184)
37. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975;111:40-48.
38. Yokota T, Nishio H, Kubota Y, Mizoguchi M. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res 1998;11:355-361. (Pubitemid 128531532)
39. Karg E, Odh G, Wittbjer A, Rosengren E, Rorsman H. Hydrogen peroxide as an inducer of elevated tyrosinase level in melanoma cells. J Invest Dermatol 1993;100(2 Suppl):209S-213S. (Pubitemid 23051700)
40. Gukasyan GS. Study of the kinetics of oxidation of monophenols by tyrosinase. The effect of reducers. Biochemistry (Mosc) 2002;67:277-280. (Pubitemid 34474103)
41. Ros JR, Rodríguez-López JN, García-Cánovas F. Effect of L-ascorbic acid on the monophenolase activity of tyrosinase. Biochem J 1993;295:309-312. (Pubitemid 23298342)
42. Ichihashi M, Funasaka Y, Ohashi A, Chacraborty A, Ahmed NU, Ueda M, et al. The inhibitory effect of DL-alpha-tocopheryl ferulate in lecithin on melanogenesis. Anticancer Res 1999;19:3769-3774.
43. Nishiyama T, Ohnishi J, Hashiguchi Y. Fused heterocyclic antioxidants: antioxidative activities of hydrocoumarins in a homogeneous solution. Biosci Biotechnol Biochem 2001;65:1127-1133. (Pubitemid 33665968)
44. Yamamura T, Onishi J, Nishiyama T. Antimelanogenic activity of hydrocoumarins in cultured normal human melanocytes by stimulating intracellular glutathione synthesis. Arch Dermatol Res 2002;294:349-354. (Pubitemid 35341027)
45. Saliou C, Kitazawa M, McLaughlin L, Yang JP, Lodge JK, Tetsuka T, et al. Antioxidants modulate acute solar ultraviolet radiation-induced NF-kappa-B activation in a human keratinocyte cell line. Free Radic Biol Med 1999;26:174-183.
46. d'Ischia M, Napolitano A, Prota G. Peroxidase as an alternative to tyrosinase in the oxidative polymerization of 5, 6-dihydroxyindoles to melanin (s). Biochim Biophys Acta 1991;1073:423-430.
47. Kasraee B. Peroxidase-mediated mechanisms are involved in the melanocytotoxic and melanogenesis-inhibiting effects of chemical agents. Dermatology 2002;205:329-339. (Pubitemid 35356757)
48. Kasraee B. Depigmentation of brown Guinea pig skin by topical application of methimazole. J Invest Dermatol 2002;118:205-207. (Pubitemid 34107444)
49. Park SH, Kim DS, Kim WG, Ryoo IJ, Lee DH, Huh CH, et al. Terrein: a new melanogenesis inhibitor and its mechanism. Cell Mol Life Sci 2004;61:2878-2885.
50. Park SH, Kim DS, Lee HK, Kwon SB, Lee S, Ryoo IJ, et al. Long-term suppression of tyrosinase by terrein via tyrosinase degradation and its decreased expression. Exp Dermatol 2009;18:562-566.